bioMerieux (BMXMF) Stock Forecast & Price Target
BMXMF Analyst Ratings
Hold
1Buy2Hold1Sell
Based on 4 analysts giving stock ratings to bioMerieux in the past 3 months
BMXMF Stock 12 Month Forecast
Average Price Target
$93.57▼(-8.39% Downside)Based on 4 Wall Street analysts offering 12 month price targets for bioMerieux in the last 3 months. The average price target is $93.57 with a high forecast of $115.42 and a low forecast of $73.96. The average price target represents a -8.39% change from the last price of $102.14.
Past 12 Months12 Month ForecastJan2026Oct2026
High$115.42
Average$93.57
Low$73.96
Highest Price TargetHighest$115.42Average Price Target$93.57Lowest Price TargetLowest$73.96
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jan Koch | Deutsche Bank | $84.04→$115.42 | buy | 13.00%Upside | Upgraded | 10/28/26 | ||
| Natalia Webster | RBC Capital | $95.25 | hold | -6.75%Downside | Reiterated | 10/23/26 | ||
| Aisyah Noor | Morgan Stanley | $71.72→$73.96 | sell | -27.59%Downside | Reiterated | 09/11/26 | ||
| Charles Pitman CFA | Barclays | $84.04→$89.65 | hold | -12.23%Downside | Reiterated | 09/07/26 | ||
| Kavya Deshpande | UBS | $89.65→$87.40 | hold | -14.43%Downside | Reiterated | 07/29/26 | ||
| David Westenberg | Piper Sandler | $89.65 | hold | -12.23%Downside | Reiterated | 07/29/26 | ||
| Pablo de Renteria | Kepler Capital | $95.25 | buy | -6.75%Downside | Reiterated | 06/25/26 | ||
| David Adlington | J.P. Morgan | $135.03→$80.23 | hold | -21.45%Downside | Reiterated | 04/24/26 | ||
| Hugo Solvet | Exane BNP Paribas | $112.06 | hold | 9.71%Upside | Downgraded | 01/28/26 | ||
| Anna Ractliffe | Bank of America Securities | $100.85→$128.87 | hold | 26.16%Upside | Upgraded | 12/12/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jan Koch | 10/28/26 | $84.04→$115.42 | buy | 13.00%Upside | Upgraded | Deutsche Bank | ||
| Natalia Webster | 10/23/26 | $95.25 | hold | -6.75%Downside | Reiterated | RBC Capital | ||
| Aisyah Noor | 09/11/26 | $71.72→$73.96 | sell | -27.59%Downside | Reiterated | Morgan Stanley | ||
| Charles Pitman CFA | 09/07/26 | $84.04→$89.65 | hold | -12.23%Downside | Reiterated | Barclays | ||
| Kavya Deshpande | 07/29/26 | $89.65→$87.40 | hold | -14.43%Downside | Reiterated | UBS | ||
| David Westenberg | 07/29/26 | $89.65 | hold | -12.23%Downside | Reiterated | Piper Sandler | ||
| Pablo de Renteria | 06/25/26 | $95.25 | buy | -6.75%Downside | Reiterated | Kepler Capital | ||
| David Adlington | 04/24/26 | $135.03→$80.23 | hold | -21.45%Downside | Reiterated | J.P. Morgan | ||
| Hugo Solvet | 01/28/26 | $112.06 | hold | 9.71%Upside | Downgraded | Exane BNP Paribas | ||
| Anna Ractliffe | 12/12/25 | $100.85→$128.87 | hold | 26.16%Upside | Upgraded | Bank of America Securities |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering bioMerieux
3 Months
Success Rate2/5 ratings generated profit
40%
Average Return
-2.70%
Copying Jan Koch's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -2.70% per trade.
1 Year
Success Rate2/5 ratings generated profit
40%
Average Return
-1.74%
Copying Jan Koch's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -1.74% per trade.
2 Years
Success Rate1/3 ratings generated profit
33%
Average Return
-19.33%
Copying Aisyah Noor's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -19.33% per trade.
BMXMF Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 0 | 1 | 1 |
| Hold | 9 | 9 | 5 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 12 | 11 | 6 | 4 | 4 |
In the current month, BMXMF has received 1 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. BMXMF average Analyst price target in the past 3 months is 93.57.
BMXMF Financial Forecast
High$2.85
Consensus$2.74
Low$2.57
BMXMF Earnings Forecast
Next quarter’s earnings estimate for BMXMF is $2.74 with a range of $2.57 to $2.85. The previous quarter’s EPS was $2.23. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
High$2.45B
Consensus$2.43B
Low$2.42B
BMXMF Sales Forecast
Next quarter’s sales forecast for BMXMF is $2.43B with a range of $2.42B to $2.45B. The previous quarter’s sales results were $2.20B. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
BMXMF Stock Forecast FAQ
What is BMXMF’s average 12-month price target, according to analysts?
Based on analyst ratings, bioMerieux’s 12-month average price target is $93.57.
What is BMXMF’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for BMXMF, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMXMF a Buy, Sell or Hold?
bioMerieux has a consensus rating of Hold which is based on 1 buy ratings, 2 hold ratings and 1 sell ratings.
What is bioMerieux’s price target?
The average price target for bioMerieux is $93.57. This is based on 4 12-month price targets, issued in the past 3 months. The highest analyst price target is $115.42, the lowest forecast is $73.96. The average price target represents a 8.39% decrease from the current price of $102.141.
What do analysts say about bioMerieux?
bioMerieux’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of BMXMF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
